Laiba Immad
2 min read
In This Article:
Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major breakthrough in treating metastatic triple-negative breast cancer (mTNBC). Trodelvy (sacituzumab govitecan-hziy) demonstrated a significant and meaningful improvement in progression-free survival compared to chemotherapy in first-line mTNBC patients who cannot receive immunotherapy. This marks the first substantial progress in over two decades for this challenging cancer subtype, fulfilling a critical unmet medical need.
A healthcare professional wearing a health communications device discussing patient data with a colleague.
These findings suggest Trodelvy could become a foundational treatment for all first-line mTNBC patients, building on positive outcomes from the ASCENT-04 study, which tested Trodelvy combined with Keytruda in PD-L1-positive mTNBC cases. The safety profile remained consistent, with no new adverse effects reported.
Following the announcement, Gilead Sciences, Inc. (NASDAQ:GILD)’s stock price rose by 6% over the past week, outperforming broader market declines amid trade and tech sector uncertainties. Investors are optimistic about Gilead’s growth prospects, driven by innovative oncology therapies. Full data from ASCENT-03 will be shared at the upcoming ASCO conference, with regulatory submissions expected to follow. This development highlights Gilead Sciences, Inc. (NASDAQ:GILD)’s growing influence in oncology and its dedication to improving outcomes for breast cancer patients worldwide.
While we acknowledge the potential of GILD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.
Disclosure: None.
